N,N'-Di-(2-ethoxy-ethyl)-piperazin | 13484-39-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: N,N'-Di-(2-ethoxy-ethyl)-piperazin
• 英文别名: 1,4-bis-(2-ethoxy-ethyl)-piperazine；1,4-Bis-(2-aethoxy-aethyl)-piperazin；Piperazine, 1,4-bis(2-ethoxyethyl)-；1,4-bis(2-ethoxyethyl)piperazine
• CAS: 13484-39-4
• 化学式: C₁₂H₂₆N₂O₂
• 分子量: 230.351
• InChiKey: KBSVKAJXWSUMCI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  16
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  24.9
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  哌嗪 、 2-乙氧基氯乙烷 在 sodium hydroxide 作用下， 生成 N,N'-Di-(2-ethoxy-ethyl)-piperazin
  参考文献：
  名称：

  Adrenergic Blocking Agents. II. Piperazines¹

  摘要：

  DOI：

  10.1021/ja01649a024

文献信息

• Method for manufacturing stabilized polyacetal resin, stabilized polyacetal resin, stabilized polyacetal resin composition, and molded article of stabilized polyacetal resin
  申请人：Polyplastics Co., Ltd.

  公开号：EP1867667A1

  公开（公告）日：2007-12-19

  The present invention provides an agent to decompose unstable terminal group, which is effective in a small adding amount, which sufficiently decreases the quantity of residual unstable terminal group, and which generates very little limitation on the treatment method, the apparatus, and the use amount of the agent. Specifically, it provides a method for manufacturing stabilized polyacetal resin having the step of applying heat treatment to a polyacetal resin having an unstable terminal group in the presence of an agent to decompose the unstable terminal group, which agent is composed of a heterocyclic quaternary ammonium salt, thus decreasing the quantity of the unstable terminal group.

  本发明提供了一种分解不稳定末端基团的药剂，其添加量小，效果好，能充分减少残留的不稳定末端基团的数量，并且对处理方法、装置和药剂的使用量限制很小。具体地说，它提供了一种制造稳定聚缩醛树脂的方法，该方法的步骤是：在有药剂存在的情况下，对具有不稳定末端基团的聚缩醛树脂进行热处理，以分解不稳定末端基团，该药剂由杂环季铵盐组成，从而减少不稳定末端基团的数量。
• TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS
  申请人：Arvinas Operations, Inc.

  公开号：EP3689868A1

  公开（公告）日：2020-08-05

  The present disclosure relates to bifunctional compounds, which find utility as modulators of estrogen receptor (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end at least one of a Von Hippel-Lindau ligand, a cereblon ligand, Inhibitors of Apoptosis Proteins ligand, mouse double-minute homolog 2 ligand, or a combination thereof, which binds to the respective E3 ubiquitin ligase, and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.

  本公开涉及双功能化合物，它们可用作雌激素受体（靶蛋白）的调节剂。特别是，本公开涉及双功能化合物，其一端含有 Von Hippel-Lindau 配体、cereblon 配体、凋亡蛋白抑制剂配体、小鼠双敏同源物 2 配体或其组合中的至少一种、其一端与相应的 E3 泛素连接酶结合，另一端与靶蛋白结合，从而将靶蛋白置于泛素连接酶附近，以实现对靶蛋白的降解（和抑制）。本公开物具有与降解/抑制靶蛋白相关的广泛药理活性。本公开的化合物和组合物可以治疗或预防因目标蛋白聚集或积聚而导致的疾病或失调。
• Method for manufacturing stabilized polyacetal resin
  申请人：Polyplastics Co., Ltd.

  公开号：EP1867667B1

  公开（公告）日：2012-10-31
• [EN] COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ENHANCER OF ZESTE HOMOLOG 2 POLYPEPTIDE<br/>[FR] COMPOSÉS ET MÉTHODES POUR LA DÉGRADATION CIBLÉE D'ACTIVATEUR DU POLYPEPTIDE HOMOLOGUE 2 DE ZESTE
  申请人：ARVINAS INC

  公开号：WO2018119357A1

  公开（公告）日：2018-06-28

  The present disclosure relates to bifunctional compounds, which find utility as modulators of enhancer of zeste homolog 2 (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a Von Hippel-Lindau, cereblon, Inhibitors of Apotosis Proteins or mouse double-minute homolog 2 ligand which binds to the respective E3 ubiquitin ligase and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.
• Adrenergic Blocking Agents. II. Piperazines¹
  作者：Ansel P. Swain、Sara K. Naegele

  DOI：10.1021/ja01649a024

  日期：1954.10